Related Experiment Videos
Ticlopidine and aspirin interactions
1Clinica Medica Generale, Università di Milano, Ospedale Maggiore IRCCS, Italy.
Insights
Comparing aspirin alone versus aspirin with ticlopidine, current multicentre trials suggest the combination therapy offers a better risk-benefit profile. This approach may improve vessel patency post-stent implantation despite potential neutropenia risks.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Cardiologists debate antiplatelet strategies post-stent implantation.
- Two main approaches exist: aggressive antiplatelet therapy (aspirin plus ticlopidine) or aspirin monotherapy with IVUS guidance.
- Neutropenia risk (0.7%) is a concern with ticlopidine, while aspirin monotherapy may lead to increased coagulation activation.
Purpose of the Study:
- To investigate the risk-benefit balance of aspirin compared to aspirin plus ticlopidine.
- To evaluate different antiplatelet strategies in multicentre trials.
- To assess the efficacy and safety of combined antiplatelet regimens versus monotherapy.
Main Methods:
- Several multicentre trials (MUSIC, WEST II, TASTE, MUST, STARS) are comparing treatment regimens.
- Cardiologists employ distinct strategies based on risk tolerance and cost-effectiveness.
- Intravascular ultrasound (IVUS) is used to ensure stent expansion and lesion coverage in monotherapy approaches.
Main Results:
- The study is ongoing, with preliminary impressions favoring the combination of ticlopidine and aspirin.
- The combination therapy appears to offer a more favorable risk-effect balance.
- Aggressive antiplatelet therapy aims to maintain vessel patency, while monotherapy prioritizes cost-saving and IVUS evaluation.
Conclusions:
- The combination of ticlopidine and aspirin is suggested to have a more favorable risk-effect balance.
- Further results from ongoing multicentre trials are anticipated to confirm these findings.
- The choice of antiplatelet strategy involves balancing efficacy, safety, and cost considerations.
Abstract:
The risk-benefit balance when aspirin is compared with aspirin combined with ticlopidine is being investigated in several multicentre trials (MUSIC and WEST II versus TASTE, MUST, and STARS respectively). Cardiologists follow one of two strategies. Some prefer a more aggressive antiplatelet regimen, disregarding the risk of neutropenia (0.7%) because they want to avoid lessening the therapeutic effect of vessel patency obtained with stent implantation. Others give only aspirin (a money saving approach) confident that IVUS inspection (an expensive approach) will allow an adequate evaluation of full stent expansion and lesion coverage, despite a more pronounced activation of the coagulation cascade. Our impression so far is that the combination of ticlopidine and aspirin has a more favourable risk-effect balance.